Hypoxia-specific cytotoxins in cancer therapy
Open Access
- 1 January 1996
- journal article
- Published by Elsevier in Seminars in Radiation Oncology
- Vol. 6 (1), 22-36
- https://doi.org/10.1016/s1053-4296(96)80033-6
Abstract
No abstract availableThis publication has 99 references indexed in Scilit:
- Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxiaEuropean Journal Of Cancer, 1994
- Tumour Hypoxia: The Picture Has Changed in the 1990sInternational Journal of Radiation Biology, 1994
- EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical modelsEuropean Journal Of Cancer, 1993
- DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomasEuropean Journal Of Cancer, 1992
- Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivativesJournal of Medicinal Chemistry, 1989
- CB 1954 (2,4-dinitro-5-aziridinyl benzamide) becomes a DNA interstrand crosslinking agent in Walker tumour cellsBiochemical and Biophysical Research Communications, 1986
- Hydralazine-enhanced selective heating of transmissible venereal tumor implants in dogsEuropean Journal of Cancer and Clinical Oncology, 1982
- Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenationThe British Journal of Radiology, 1979
- Mammalian cell toxicity of nitro compounds: Dependence upon reduction potentiaklBiochemical and Biophysical Research Communications, 1976
- Tumour-growth inhibitorynitrofphenylaziridines and related compounds structure-activity relationshipsChemico-Biological Interactions, 1969